Seminars in Nuclear Medicine
Volume 37, Issue 5 , Pages 316-331 , September 2007

PET and PET/CT in Pediatric Oncology

  • Hossein Jadvar, MD, PhD, MPH, MBA

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
    • ,
  • Leonard P. Connolly, MD

      Affiliations

    • Division of Nuclear Medicine, Children’s Hospital Boston, Harvard Medical School, Boston, MA.
    • ,
  • Frederic H. Fahey, DSc

      Affiliations

    • Division of Nuclear Medicine, Children’s Hospital Boston, Harvard Medical School, Boston, MA.
    • ,
  • Barry L. Shulkin, MD, MBA

      Affiliations

    • Division of Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, TN.
    • Corresponding Author InformationAddress reprint requests to Barry L. Shulkin, MD, MBA, Director, Division of Nuclear Medicine, St. Jude Children’s Research Hospital, 332 North Lauderdale, MS 752, Memphis, TN 38105.

References 

  1. Gordon I. Issues surrounding preparation, information, and handling the child and parent in nuclear medicine. J Nucl Med. 1998;39:490–494
  2. Treves ST. Introduction. In:  Treves ST editors. Pediatric Nuclear Medicine. 2nd ed.. New York: Springer-Verlag; 1995;p. 1–11
  3. Shulkin BL. PET imaging in pediatric oncology. Pediatr Radiol. 2004;34:199–204
  4. Mandell GA, Cooper JA, Majd M, et al. Procedure guidelines for pediatric sedation in nuclear medicine. J Nucl Med. 1997;38:1640–1643
  5. American Academy of PediatricsCommittee on Drugs. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics. 1992;89:1110–1115
  6. American Society of Anesthesiologists, Task Force on Sedation and Analgesia by Non-Anesthesiologists: Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 96:1004-1017
  7. Shulkin BL. PET applications in Pediatrics. Q J Nucl Med. 1997;41:281–291
  8. Townsend DW, Beyer T. A combined PET/CT scanner: The path to true image fusion. Br J Radiol. 2002;75(suppl):S24–S30
  9. Kaste SC. Issues specific to implementing PET/CT for pediatric oncology: what we have learned along the way. Pediatr Radiol. 2004;34:205–213
  10. Borgwardt L, Larsen HJ, Pedersen K, et al. Practical use and implementation of PET in children in a hospital PET center. Eur J Nucl Med Mol Imaging. 2003;30:1389–1397
  11. Beyer T, Antoch G, Muller S, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45(suppl 1):25S–35S
  12. Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography—clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med. 2003;33:228–237
  13. Visvikis D, Costa DC, Croasdale I, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging. 2003;30:344–353
  14. Nehmeh SA, Erdi YE, Kalaigian H, et al. Correction for oral contrast artifacts in CT attenuation-corrected PET images obtained by combined PET/CT. J Nucl Med. 2003;44:1940–1944
  15. Dizendorf EV, Treyer V, von Schulthess GK, et al. Application of oral contrast media in coregistered positron emission tomography-CT. AJR Am J Roentgenol. 2002;179:477–481
  16. Yeung HW, Sanches A, Squire OD, et al. Standardized uptake value (SUV) in pediatric patients: An investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging. 2002;29:61–66
  17. Schelbert H, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using Fluorine-18-FDG. J Nucl Med. 1998;39:1302–1305
  18. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG-PET/CT 1.0. J Nucl Med. 2006;47:885–895
  19. Jones SC, Alavi A, Christman D, et al. The radiation dosimetry of 2-[18F]fluoro-2-deoxy-D-glucose in man. J Nucl Med. 1982;23:613–617
  20. Ruotsalainen U, Suhonen-Povli H, Eronen E, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med. 1996;37:387–393
  21. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001;176:289–296
  22. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Cancer. 1995;75:2186–2195
  23. Robison L. General principles of the epidemiology of childhood cancer. In:  Pizzo P,  Poplack D editor. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott-Raven; 1997;p. 1–10
  24. Franzius C, Schober O. Assessment of therapy response by FDG-PET in pediatric patients. Q J Nucl Med. 2003;47:41–45
  25. Wegner EA, Barrington SF, Kingston JE, et al. The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging. 2005;32:23–30
  26. Pacak K, Ilias I, Chen CC, et al. The role of 18F-fluorodeoxyglucose positron emission tomography and In-111-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome. J Clin Endocrinol Metab. 2004;89:2214–2221
  27. Figarola MS, McQuiston SA, Wilson F, et al. Recurrent hepatoblastoma with localization by PET/CT. Pediatr Radiol. 2005;35:1254–1258
  28. Kinoshita H, Shimotake T, Furukawa T, et al. Mucoepidermal carcinoma of the lung detected by positron emission tomography in a 5-year-old girl. J Pediatr Surg. 2005;40:E1–E3
  29. Philip I, Shun A, McCowage G, et al. Positron emission tomography in recurrent hepatoblastoma. Pediatr Surg Int. 2005;21:341–345
  30. Franzius C, Juergens KU, Vomoor J. PET/CT with diagnostic CT in the evaluation of childhood sarcoma. AJR Am J Roentgenol. 2005;184:1293–1304
  31. Sasi OA, Sathiapalan R, Rifai A, et al. Colonic neuroendocrine carcinoma in a child. Pediatr Radiol. 2005;35:339–343
  32. Buchler T, Cervinek L, Belohlavek O, et al. Langerhans cell histiocytosis with central nervous system involvement: follow up by FDG-PET during treatment with cladribine. Pediatr Blood cancer. 2005;44:286–288
  33. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:2665–2671
  34. Mody RJ, Pohlen JA, Malde S, et al. FDG-PET for the study of primary hepatic malignancies in children. Pediatr Blood Cancer. 2006;47:51–55
  35. Bar-Sever Z, Keidar Z, Ben-Barak A, et al. The incremental value of (18)F-FDG PET/CT in pediatric malignancies. Eur J Nucl Med Mol Imaging. 2007;34:630–637
  36. Nanni C, Rubello D, Castelluci P, et al. 18F-FDG-PET/CT fusion imaging in pediatric solid extracranial tumors. Biomed Pharmacother. 2006;60:593–606
  37. Yeung HW, Schoder H, Smith A, et al. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography studies in cancer patients. Mol Imaging Biol. 2005;7:229–235
  38. Moon L, McHugh K. Advances in pediatric tumor imaging. Arch Dis Child. 2005;90:608–611
  39. Weinblatt ME, Zanzi I, Belakhlef A, et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin’s disease. J Nucl Med. 1997;38:888–890
  40. Patel PM, Alibazoglu H, Ali A, et al. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med. 1996;21:772–775
  41. Delbeke D. Oncological applications of FDG-PET Imaging: Colorectal cancer, lymphoma, and melanoma. J Nucl Med. 1999;40:591–603
  42. Yeung HW, Grewal RK, Gonen M, et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: A potential source of false-positives for PET. J Nucl Med. 2003;44:1789–1796
  43. Minotti AJ, Shah L, Keller K. Positron emission tomography/computed tomography fusion imaging in brown adipose tissue. Clin Nucl Med. 2004;29:5–11
  44. Hany TF, Gharehpapagh E, Kamel EM, et al. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002;29:1393–1398
  45. Cohade C, Osman M, Pannu HK, et al. Uptake in supraclavicular area fat (“USA-Fat”): Description on 18F-FDG-PET/CT. J Nucl Med. 2003;44:170–176
  46. Sugawara Y, Fisher SJ, Zasadny KR, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173–180
  47. Hollinger EF, Alibazoglu H, Ali A, et al. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23:93–98
  48. Brink I, Reinhardt MJ, Hoegerle S, et al. Increased metabolic activity in the thymus gland studied with 18F-FDG-PET: age dependency and frequency after chemotherapy. J Nucl Med. 2001;42:591–595
  49. Truong MT, Erasmus JJ, Munden RF, et al. Focal FDG uptake in mediastinal brown fat mimicking malignancy: A potential pitfall resolved on PET/CT. AJR Am J Roentgenol. 2004;183:1127–1132
  50. Tatsumi M, Engles JM, Ishimori T, et al. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med. 2004;45:1189–1193
  51. Gelfand MJ, O’Hara SM, Curtwright LA, et al. Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiol. 2005;35:984–990
  52. Garcia CA, Van Nostrand D, Atkins F, et al. Reduction of brown fat 2-deoxy-2-[F-18]fluoro-D-glucose uptake by controlling environmental temperature prior to positron emission tomography scan. Mol Imaging Biol. 2006;8:24–29
  53. Goodin GS, Shulkin BL, Kaufman RA, et al. PET/CT characterization of fibroosseous defects in children: 18F-FDG uptake can mimic metastatic disease. AJR Am J Roentgenol. 2006;187:1146
  54. Feldman F, vanheertum R, Saxena C. 18Fluorodeoxyglucose positron emission tomography evaluation of benign versus malignant osteochondromas: Preliminary observations. J Comput Assist Tomogr. 2006;30:858–864
  55. Bujenovic S, Mannting F, Chakrabarti R, et al. Artifactual 2-deoxy-2-[(18)F]fluoro-D-deoxyglucose localization surrounding metallic objects in a PET/CT scanner using CT-based attenuation correction. Mol Imaging Biol. 2003;5:20–22
  56. Nakamoto Y, Chin RB, Kraitchman DL, et al. effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology. 2003;227:817–824
  57. Kleihues P, Burger P, Scheithauer B. The new WHO classification of brain tumors. Brain Pathol. 1993;3:255–268
  58. Robertson R, Ball WJ, Barnes P. Skull and brain. In:  Kirks D editors. Practical Pediatric Imaging (Diagnostic Radiology of Infants and Children). Philadelphia: Lippincott-Raven; 1997;p. 65–200
  59. Maria B, Drane WB, Quisling RJ, et al. Correlation between gadolinium-diethylenetriaminepentaacetic acid contrast enhancement and thallium-201 chloride uptake in pediatric brainstem glioma. J Child Neurol. 1997;12:341–348
  60. O’Tuama L, Janicek M, Barnes P, et al. Tl-201/Tc-99m HMPAO SPECT imaging of treated childhood brain tumors. Pediatr Neurol. 1991;7:249–257
  61. O’Tuama L, Treves ST, Larar G, et al. Tl-201 versus Tc-99m MIBI SPECT in evaluation of childhood brain tumors. J Nucl Med. 1993;34:1045–1051
  62. Rollins N, Lowry P, Shapiro K. Comparison of gadolinium-enhanced MR and thallium-201 single photon emission computed tomography in pediatric brain tumors. Pediatr Neurosurg. 1995;22:8–14
  63. Valk PE, Budinger TF, Levin VA, et al. PET of malignant cerebral tumors after interstitial brachytherapy (Demonstration of metabolic activity and correlation with clinical outcome). J Neurosurg. 1988;69:830–838
  64. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. 1988;150:189–197
  65. Glantz MJ, Hoffman JM, Coleman RE, et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomograph. Ann Neurol. 1991;29:347–355
  66. Janus T, Kim E, Tilbury R, et al. Use of [18F] fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol. 1993;33:540–548
  67. Rozental JM, Levine RL, Nickles RJ. Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance. J Neuro-Oncol. 1991;10:75–83
  68. Pirotte B, Goldman S, Salzberg S, et al. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg. 2003;38:146–155
  69. Schifter T, Hoffman JM, Hanson MW, et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr. 1993;17:509–561
  70. Borgwardt L, Hojgaard L, Carstensen H, et al. Increased fluorine-18 2-fluoro-2-deoxy D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol. 2005;23:3030–3037
  71. Francavilla TL, Miletich RS, Di Chiro G, et al. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery. 1989;24:1–5
  72. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985;62:816–822
  73. Bruggers CS, Friedman HS, Fuller GN, et al. Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma. Med Pediatr Oncol. 1993;21:301–306
  74. Molloy PT, Belasco J, Ngo K, et al. The role of FDG-PET imaging in the clinical management of pediatric brain tumors. J Nucl Med. 1999;40:129P
  75. Holthof VA, Herholz K, Berthold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer. 1993;1394–1403
  76. Hoffman JM, Hanson MW, Friedman HS, et al. FDG-PET in pediatric posterior fossa brain tumors. J Comput Assist Tomogr. 1992;16:62–68
  77. Gururangan S, Hwang E, Herndon JE, et al. [18F]fluorodeoxyglucose positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004;55:1280–1288
  78. Wang SX, Boethus J, Ericson K. FDG-PET on irradiated brain tumor: ten years summary. Acta Radiol. 2006;47:85–90
  79. Molloy PT, Defeo R, Hunter J, et al. Excellent correlation of FDG-PET imaging with clinical outcome in patients with neurofibromatosis type I and low grade astrocytomas. J Nucl Med. 1999;40:129P
  80. Pirotte B, Goldman S, Dewitte O, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: A report of 103 consecutive procedures. J Neurosurg. 2006;104:238–253
  81. O’Tuama LA, Phillips PC, Strauss LC, et al. Two-phase [11C]L-methionine PET in childhood brain tumors. Pediatr Neurol. 1990;6:163–170
  82. Mosskin M, von Holst H, Bergstrom M, et al. Positron emission tomography with 11C-methionine and computed tomography of intracranial tumors compared with histopathologic examination of multiple biopsies. Acta Radiol. 1987;28:673–681
  83. Utriainen M, Metsahonkala L, Salmi TT, et al. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer. 2002;95:1376–1386
  84. Torii K, Tsuyuguchi N, Kawabe J, et al. Correlation of amino-acid uptake using methionine PET and histological classification in various gliomas. Ann Nucl Med. 2005;19:677–683
  85. Lilja A, Lundqvist H, Olsson Y, et al. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesion. Acta Radiol. 1989;38:121–128
  86. Pirotte B, Levivier M, Morelli D, et al. Positron emission tomography for the early postsurgical evaluation of pediatric brain tumors. Childs Nerv Syst. 2005;21:294–300
  87. Ceyssens S, Van Laere K, de Groot T, et al. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neurolradiol. 2006;27:1432–1437
  88. Mineura K, Sasajima T, Kowada M, et al. Indications for differential diagnosis of nontumor central nervous system diseases from tumors (A positron emission tomography study). J Neuroimaging. 1997;7:8–15
  89. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: Sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39–51
  90. Choi SJ, Kim JS, Kim JH, et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653–659
  91. Juhasz C, Chugani DC, Muzik O, et al. In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors. J Cereb Blood Flow Metab. 2006;26:345–357
  92. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: Positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318–327
  93. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678–687
  94. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:422–429
  95. Kaste SC, Howard SC, McCarville EB, et al. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin’s. Pediatr Radiol. 2005;35:141–154
  96. Cohen MD. Imaging of Children with Cancer. St. Louis: Mosby Yearbook; 1992;
  97. Nadel HR, Rossleigh MA. Tumor imaging. In:  Treves ST editors. Pediatric Nuclear Medicine. (ed 2). New York: Springer-Verlag; 1995;p. 496–527
  98. Rossleigh MA, Murray IPC, Mackey DWJ. Pediatric solid tumors: Evaluation by gallium-67 SPECT studies. J Nucl Med. 1990;31:161–172
  99. Howman-Giles R, Stevens M, Bergin M. Role of gallium-67 in management of pediatric solid tumors. Aust Pediatric J. 1982;18:120–125
  100. Yang SL, Alderson PO, Kaizer HA, et al. Serial Ga-67 citrate imaging in children with neoplastic disease: concise communication. J Nucl Med. 1979;20:210–214
  101. Sty JR, Kun LE, Starshak RJ. Pediatric applications in nuclear oncology. Semin Nucl Med. 1985;15:171–200
  102. Barrington SF, Carr R. Staging of Burkitt’s lymphoma and response to treatment monitored by PET scanning. Clin Oncology. 1995;7:334–335
  103. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol. 1998;9:1117–1122
  104. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG-PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Nucl Med Commun. 1999;20:13–20
  105. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: A PET study. J Nucl Med. 1991;32:1211–1218
  106. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603–609
  107. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: Detection with FDG-PET versus CT. Radiology. 1998;206:475–481
  108. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997;203:795–800
  109. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med. 1991;32:686–691
  110. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J Nucl Med. 1992;33:325–329
  111. Rodriguez M, Rehn S, Ahlstrom H, et al. Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med. 1995;36:1790–1796
  112. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987;28:288–292
  113. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology. 1994;190:111–116
  114. de Wit M, Bumann D, Beyer W, et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997;8(suppl 1):57–60
  115. Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18-F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055–1063
  116. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med. 1997;38:343–348
  117. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin’s lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464–4471
  118. Stumpe KD, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998;25:721–728
  119. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995;86:3522–3527
  120. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340–3346
  121. Segall GM. FDG-PET imaging in patients with lymphoma: A clinical perspective. J Nucl Med. 2001;42:609–610
  122. Moody R, Shulkin B, Yanik G, et al. PET FDG imaging in pediatric lymphomas. J Nucl Med. 2001;42(5 suppl):39P
  123. Kostakoglu L, Leonard JP, Coleman M, et al. Comparison of FDG-PET and Ga-67 SPECT in the staging of lymphoma. J Nucl Med. 2000;41(5 suppl):118P
  124. Tatsumi M, Kitayama H, Sugahara H, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin’s lymphoma. J Nucl Med. 2001;42:601–608
  125. Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin’s lymphoma. Pediatr Radiol. 2004;34:190–198
  126. Montravers F, McNamara D, Landman-Parker J, et al. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging. 2002;29:1155–1165
  127. Depas G, De Barsy C, Jerusalem G, et al. 18F-FDG-PET in children with lymphomas. Eur J Nucl Med Mol Imaging. 2005;32:31–38
  128. Amthauer H, Furth C, Denecke T, et al. FDG-PET in 10 children with non-Hodgkin’s lymphoma: Initial experience in staging and follow-up. Klin Pediatr. 2005;217:327–333
  129. Hernandez-Pampaloni M, Takalkar A, Yu JQ, et al. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol. 2006;36:524–531
  130. Kabickova E, Sumerauer D, Cumlivska E, et al. Comparison of (18)F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur J Nucl Med Mol Imaging. 2006;33:1025–1031
  131. Keresztes K, Lengyel Z, Devenyi K, et al. Mediastinal bulky tumor in Hodgkin’s disease and prognostic value of positron emission tomography in the evaluation of post treatment residual masses. Acta Haematol. 2004;112:194–199
  132. Lavely WC, Delbeke D, Greer JP, et al. FDG-PET in the follow-up of management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:307–315
  133. Filmont JE, Yap CS, Ko F, et al. Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin’s disease. Mol Imaging Biol. 2004;6:47–54
  134. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol. 2006;28:711–714
  135. Meany HJ, Gidvani VK, Minniti CP. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer. 2007;48:399–402
  136. Tatsumi M, Cohade C, Nakamoto Y, et al. Direct comparison of FDG-PET and CT findings in patients with lymphoma: Initial experience. Radiology. 2005;237:1038–1045
  137. Furth C, Denecke T, Steffen I, et al. Correlative imaging strategies implementing CT, MR, and PET for staging of childhood Hodgkin disease. J Pediatr Hematol Oncol. 2006;28:501–512
  138. Miller E, Metser U, Avrahami G, et al. Role of 18F-FDG-PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr. 2006;30:689–694
  139. Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28:300–306
  140. Swift P. Novel techniques in the delivery of radiation in pediatric oncology. Pediatr Clin North Am. 2002;49:1107–1129
  141. Korholz D, Kluge R, Wickmann L, et al. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin’s lymphoma in childhood and adolescence—consequences for the GPOH-HD 2003 protocol. Onkologie. 2003;26:489–493
  142. Krasin MJ, Hudson MM, Kaste SC. Positron emission tomography in pediatric radiation oncology: Integration in the treatment-planning process. Pediatr Radiol. 2004;34:214–221
  143. Bousvaros A, Kirks DR, Grossman H. Imaging of neuroblastoma: An overview. Pediatr Radiol. 1986;16:89–106
  144. Briganti V, Sestini R, Orlando C, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumor. Clin Cancer Res. 1997;3:2385–2391
  145. Shulkin BL, Hutchinson RJ, Castle VP, et al. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743–750
  146. Shulkin BL, Wieland DM, Baro ME, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37:16–21
  147. Shulkin BL, Wieland DM, Castle VP, et al. Carbon-11 epinephrine PET imaging of neuroblastoma. J Nucl Med. 1999;40:129P
  148. Franzius C, Hermann K, Weckesser M, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic system: Feasibility study and comparison with 123I-MIBG SPECT-CT. J Nucl Med. 2006;47:1635–1642
  149. Brink I, Schaefer O, Walz , et al. Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med. 2006;31:39–41
  150. Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med. 1995;36:644–650
  151. Ott RJ, Tait D, Flower MA, et al. Treatment planning for 131I-mIBG radiotherapy of neural crest tumors using 124I-mIBG positron emission tomography. Br J Radiol. 1992;65:787–791
  152. Barnewolt CE, Paltiel HJ, Lebowitz RL, et al. Genitourinary system. In:  Kirks DR editors. Practical Pediatric Imaging (Diagnostic Radiology of Infants and Children). (ed 3). Philadelphia: Lippincott-Raven; 1997;p. 1009–1170
  153. Shulkin BL, Chang E, Strouse PJ, et al. PET FDG studies of Wilms tumors. J Pediatr Hem/Oncol. 1997;19:334–338
  154. McDonald DJ. Limb salvage surgery for sarcomas of the extremities. AJR Am J Roentgenol. 1994;163:509–513
  155. Triche TJ. Pathology of pediatric malignancies. In:  Pizzo PA,  Poplack DG editor. Principles and Practice of Pediatric Oncology. (ed 2). Philadelphia: JB Lippincott; 1993;p. 115–152
  156. O’Connor MI, Pritchard DJ. Ewing’s sarcoma (Prognostic factors, disease control, and the reemerging role of surgical treatment). Clin Orthop. 1991;262:78–87
  157. Jaramillo D, Laor T, Gebhardt M. Pediatric musculoskeletal neoplasms (Evaluation with MR imaging). MRI Clin North Am. 1996;4:1–22
  158. Frouge C, Vanel D, Coffre C, et al. The role of magnetic resonance imaging in the evaluation of Ewing sarcoma—a report of 27 cases. Skeletal Radiol. 1988;17:387–392
  159. MacVicar AD, Olliff JFC, Pringle J, et al. Ewing sarcoma: MR imaging of chemotherapy-induced changes with histologic correlation. Radiology. 1992;184:859–864
  160. Lemmi MA, Fletcher BD, Marina NM, et al. Use of MR imaging to assess results of chemotherapy for Ewing sarcoma. AJR Am J Roentgenol. 1990;155:343–346
  161. Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: Assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990;175:791–796
  162. Holscher HC, Bloem JL, Vanel D, et al. Osteosarcoma: chemotherapy-induced changes at MR imaging. Radiology. 1992;182:839–844
  163. Lawrence JA, Babyn PS, Chan HS, et al. Extremity osteosarcoma in childhood: Prognostic value of radiologic imaging. Radiology. 1993;189:43–47
  164. Connolly LP, Laor T, Jaramillo D, et al. Prediction of chemotherapeutic response of osteosarcoma with quantitative thallium-201 scintigraphy and magnetic resonance imaging. Radiology. 1996;201:349
  165. Lin J, Leung WT. Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma. Eur J Nucl Med. 1995;22:553–555
  166. Menendez LR, Fideler BM, Mirra J. Thallium-201 scanning for the evaluation of osteosarcoma and soft tissue sarcoma. J Bone Joint Surg. 1993;75:526–531
  167. Ramanna L, Waxman A, Binney G, et al. Thallium-201 scintigraphy in bone sarcoma: Comparison with gallium-67 and technetium-99m MDP in the evaluation of chemotherapeutic response. J Nucl Med. 1990;31:567–572
  168. Rosen G, Loren GJ, Brien EW, et al. Serial thallium-201 scintigraphy in osteosarcoma (Correlation with tumor necrosis after preoperative chemotherapy). Clin Orthop. 1993;293:302–306
  169. Ohtomo K, Terui S, Yokoyama R, et al. Thallium-201 scintigraphy to assess effect of chemotherapy to osteosarcoma. J Nucl Med. 1996;37:1444–1448
  170. Bar-Sever Z, Connolly LP, Treves ST, et al. Technetium-99m MIBI in the evaluation of children with Ewing’s sarcoma. J Nucl Med. 1997;38:13P
  171. Caner B, Kitapel M, Unlu M, et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: A comparative study with technetium-99m-MDP. J Nucl Med. 1992;33:319–324
  172. Lenzo NP, Shulkin B, Castle VP, et al. FDG-PET in childhood soft tissue sarcoma. J Nucl Med. 2000;41(5 suppl):96P
  173. Abdel-Dayem HM. The role of nuclear medicine in primary bone and soft tissue tumors. Semin Nucl Med. 1997;27:355–363
  174. Shulkin BL, Mitchell DS, Ungar DR, et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology. 1995;194:495–500
  175. Franzius C, Sciuk J, Brinkschmidt C, et al. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874–881
  176. Hawkins DS, Rajendran JG, Conrad EU, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer. 2002;94:3277–3284
  177. Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumors of the long bones in children: Monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol. 2004;34:595–605
  178. Jadvar H, Alavi A, Mavi A, et al. PET in pediatric diseases. Radiol Clin North Am. 2005;43:135–152
  179. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828–8834
  180. Gyorke T, Zajic T, Lange A, et al. Impact of FDG-PET for staging of Ewing sarcomas and primitive neuroectodermal tumors. Nucl Med Commun. 2006;27:17–24
  181. Huang TL, Liu RS, Chen TH, et al. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma. J Chin Med Assoc. 2006;69:372–376
  182. Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumors: Comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305–1311
  183. Kneisl JS, Patt JC, Johnson JC, et al. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas?. Clin Orthop Relat Res. 2006;450:101–104
  184. Ben Arush MW, Israel O, Kedar Z, et al. Detection of isolated distant metastasis in soft tissue sarcoma by fluorodeoxyglucose positron emission tomography: case report. Pediatr Hematol Oncol. 2001;18:295–298
  185. Ben Arush MW, Bar Shalom R, Potovsky S, et al. Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol. 2006;28:440–445
  186. Peng F, Rabkin G, Muzik O. Use of 2-deoxy-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: Report of a retrospective case. Clin Nucl Med. 2006;31:394–397
  187. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339–348
  188. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, et al. Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer. 2005;45:265–273
  189. Roebuck DJ, Perilongo G. Hepatoblastoma: an oncological review. Pediatr Radiol. 2006;36:183–186
  190. Mody RJ, Pohlen JA, Malde S, et al. FDG-PET for the study of primary hepatic malignancies in children. Pediatr Blood Cancer. 2006;47:51–55

PII: S0001-2998(07)00052-9

doi: 10.1053/j.semnuclmed.2007.04.001

Seminars in Nuclear Medicine
Volume 37, Issue 5 , Pages 316-331 , September 2007

Article Tools

* Image Usage & Resolution